Articles On Adalta (ASX:1AD)

Title Source Codes Date
Check Up: Money managers are still bullish on Healthcare; here’s what they said

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

Stockhead 1AD 4 weeks ago
Check Up: Biotechs are going through a rough patch, but recent ASX IPOs haven’t flopped too badly

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Stockhead 1AD 1 month ago
CBA, NAB, ANZ: Why are these banking stocks in news in April?

Highlights Today, the S&P/ASX 200 Financial sector (ASX:XFJ) traded approximately 0.843% lower at 6730.100 points at 12:06 PM AEDT. The benchmark index ASX200 was trading 0.528% lower at 7450.600 points at 11:23 AM AEST. Three ASX...

Kalkine Media 1AD 1 month ago
AdAlta (ASX:1AD) bags first Indian patent for i-body technology platform

Highlights AdAlta’s lead i-body candidate AD-214 has bagged its first Indian patent. The patent entitled “CXCR4 binding molecules” is valid till 08 January 2036 AdAlta aims to partner with other biopharmaceutical companies to maximise...

Kalkine Media 1AD 1 month ago
ASX Health Stocks: AdAlta gets patent in India, RhinoMed starts selling in Canada

AdAlta gets first patent in India RhinoMed to start selling Covid swaps and RAT kits in Canada AdAlta (ASX:1AD) has received an Indian patent for its lead program, AD-214. The new patent protects the i-body sequence used in AD-214, as wel...

Stockhead 1AD 1 month ago
Market Highlights and 5 ASX Small Caps to watch on Thursday

The US Fed plans to reduce its bond back by US$95bn a month Nasdaq plunged another 2% ASX to open lower this morning Wall Street skids on US Fed’s plan Aussie shares are poised to follow Wall Street into the red today, with the ASX 200 Ap...

Stockhead 1AD 1 month ago
Check Up: More clinical trials and FDA funding boost. Is this the end of biotech’s woes?

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Stockhead 1AD 1 month ago
ASX Health Stocks: Cannabis biotech Emyria all set for Phase 1 clinical trial of lead CBD drug

The ASX 200 Health Index (XHJ) is up by 0.30% at the time of writing, compared to the broader index which is up by 0.60%. Clinical stage cannabis biotech, Emyria (ASX: EMD), announced that participant recruitment, screening and consenting h...

Stockhead 1AD 2 months ago
Check Up: The future of telehealth, and the best and worst performing ASX health stocks for the month

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

Stockhead 1AD 2 months ago
AdAlta (ASX:1AD) granted Chinese patent for AD-214 product

AdAlta (1AD) has been granted a patent for its lead product AD-214 by the China National Intellectual Property Administration The new patent protects the i-body sequence used in AD-214 and pharmaceutical compositions and diagnostic applica...

themarketherald.com.au 1AD 2 months ago
ASX Health Stocks: MVP’s ‘green whistle’ has finally got to Phase 3 in the US after FDA decision

The ASX 200 Health Index (XHJ) is trading lower by 0.27% at the time of writing, compared to the broader index which is falling by 0.56%. Pain relief specialist Medical Development International (ASX:MVP) announced that the US FDA has uncon...

Stockhead 1AD 2 months ago
Market Highlights and 5 ASX Small Caps to watch on Wednesday

Wall Street tumbles, ASX to fall as oil prices spike Aussie shares are set to follow Wall Street into the red today, as oil prices surged by as much as 10% overnight. As fighting in the Ukraine intensified, the US and other major economies...

Stockhead 1AD 2 months ago
Check Up: Johnson & Johnson manoeuvre causes a stir, as CSL pulls Healthcare higher on the ASX

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

Stockhead 1AD 3 months ago
Webinar Recap – TNR, LBT, 1AD & LIT

ShareCafeWebinar Recap – TNR, LBT, 1AD & LIT Catch up on the full webinar with presentations from Torian Resources (ASX: TNR), LBT Innovations (ASX: LBT),  Adalta (ASX: 1AD) & Lithium Australia (ASX: LIT) Webinar Recap – TNR...

ShareCafe 1AD 4 months ago
AdAlta (ASX: 1AD) – Webinar Presentation

ShareCafeAdAlta (ASX: 1AD) – Webinar Presentation Tim Oldham – CEO and Managing Director – AdAlta is a clinical-stage biotechnology company that uses its i-body platform to discover and develop next-generation protein therapeutics addressi...

ShareCafe 1AD 4 months ago
Check Up: As Omicron rages, rapid antigen testing specialist Atomo surges nearly 50pc

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

Stockhead 1AD 4 months ago
Check Up: Anteotech riding high with $1.9m refund, and Avecho inks supply agreement for CBD arthritis treatment

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

Stockhead 1AD 5 months ago
Healthcare has been a hot sector. Here are the top ASX biotech stocks in 2021

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

Stockhead 1AD 5 months ago
Closing Bell: Energy and financial stocks fall sharply as the ASX starts the week on a downer

The ASX started the week lower as a result of a drop in the energy and financial sectors. Energy shares fell by over 3%, as surging cases of the Omicron variant raised fears that new restrictions may hit fuel demand. Financials meanwhile we...

Stockhead 1AD 5 months ago
AdAlta (ASX:1AD) gets commitments for $3.75m placement

Clinical-stage biotech company AdAlta (1AD) is looking to raise up to $5.95 million through a placement and non-renounceable entitlement offer The company received commitments from investors for the placement, which is raising $3.75 millio...

themarketherald.com.au 1AD 5 months ago
Closing Bell: Energy, resources and property lead the ASX as ‘Santa rally’ appears on track

The so-called ‘Santa Claus Rally’ appears to be happening again this year with the ASX notching another positive day. The ASX 200 closed at 7,379 points which was 0.35% higher than Friday, following on from a 1.6% gain last week and positiv...

Stockhead 1AD 5 months ago
Closing Bell: ASX edges lower ahead of all-important US inflation data

For the first time in over a month, the ASX finished a week higher than where it began — even with the bourse declining on an intraday basis. The ASX 200 closed at 7,353 points which was 0.42% lower than yesterday, but up 1.6% from last Fri...

Stockhead 1AD 5 months ago
AdAlta (ASX:1AD) enters trading halt following positive AD-214 outcomes

Clinical-stage drug developer AdAlta (1AD) has entered a trading halt while it plans and completes a capital raise 1AD recently announced positive outcomes from early testing of its AD-214 drug candidate which is being developed for future...

themarketherald.com.au 1AD 5 months ago
ASX Health Stocks: Aussie biotechs Argenica and Antisense take major steps in the US

The ASX 200 Health Index (XHJ) is down by 0.20% at the time of writing, compared to the broader index which is down by 0.35%. Brain-focused company, Argenica Therapeutics (ASX:AGN), has just been awarded a US patent relating to the use of i...

Stockhead 1AD 5 months ago
Check Up: Neuren close to FDA drug approval and Compumedics fires up Aussie factory for medical wearables

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

Stockhead 1AD 5 months ago
Check Up: Sustainable Nutrition riding high and Singular Health branches out from… health

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Stockhead 1AD 6 months ago
Market Highlights and 5 ASX Small Caps to watch on Thursday

Wall Street retreats overnight All three US stock market indexes retreated overnight, with the Dow Jones falling by 0.58% , the S&P 500 by 0.26%, and tech heavy Nasdaq by 0.33%. US retailer Target’s Q3 revenues smashed estimates, but co...

Stockhead 1AD 6 months ago
AdAlta announces transfer of BTB funding agreement to AD-214 inhaled program

AdAlta (ASX:1AD) has announced an amendment to its funding agreement with MTPConnect under the Australian Government’s MRFF’s Biomedical Translation Bridge program with the support of UniQuest.

BiotechDispatch 1AD 7 months ago
Closing Bell: ASX has its worst day since February, suffering 2.1pc drop

Australia’s bourse had its biggest decline since February 26 falling by over 2%. The ASX 200 fell 2.1% to close at 7,248 and is down 5% since August 13. The ASX Emerging Companies Index fared worse, losing over 4% in its worst day since Apr...

Stockhead 1AD 8 months ago
Check Up: Dimerix and ImpediMed announced breakthroughs, while earnings dominate news flow in August

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

Stockhead 1AD 8 months ago
CAR-T therapy is potentially a $20bn market. Here’s how it works and the ASX players in the space

The CAR T-cell therapy (Chimeric Antigen Receptor) has been billed as a radical new way to cure cancer. But since the US FDA approved the first cell-gene therapy to treat leukemia in 2018, the technology has not really caught on in the main...

Stockhead 1AD 8 months ago
ASX Announcement: AdAlta and Carina Biotech to develop next-generation CAR-T cancer therapeutics

Highlights: AdAlta and Carina Biotech enter a collaboration agreement to develop i-body enabled CAR-T cancer immunotherapies against up to five solid tumour antigen targets Combining Carina’s advanced CAR-T platform technologies with AdAl...

FNArena 1AD 9 months ago
Closing Bell: Energy shares push ASX higher

It was another positive close for the Australian bourse today with energy the standout sector. The ASX 200 closed 0.17% higher at 7,503 points while the ASX Emerging Companies Index gained 1.1% to close at 2,262 points. Leading the charge w...

Stockhead 1AD 9 months ago
ASX Health Stocks: Nanosonics jumps almost 20% as revenue momentum picks up steam

Leading the health stocks today is Nanosonics (ASX:NAN)  up 19.69% after flagging FY21 revenues of $103.1 million, with strong momentum in H2 where revenues came in at $60 million – up 39% from H1. The company installed 3,030 units of its a...

Stockhead 1AD 9 months ago
AdAlta and Carina in new collaboration focused on CAR-T candidates

AdAlta Limited (ASX:1AD) and Carina Biotech have announced a collaboration agreement to develop next-generation i-body enabled CAR-T cells.

BiotechDispatch 1AD 9 months ago
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

Stockhead 1AD 9 months ago
Check Up: Hexima roars 70pc on clinical trials, while Bionomics heads for a US dual listing

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Stockhead 1AD 9 months ago
Hot Money Monday: Tasmanian whisky group Lark Distilling heated up in July

Whisky manufacturer Lark Distilling Co (ASX:LRK) kept things warm during winter, leading a group of 25 stocks that posted a 14-day RSI above 70 last week. Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relat...

Stockhead 1AD 10 months ago
Closing Bell: ASX 200 extends gains despite more COVID cases

Australian shares have extended gains for the second day in a row, rising by 0.91% despite more COVID cases across states. All 11 sectors were in the green, except for Healthcare. Mining and Energy led the gains, rising by 2% each, buoyed b...

Stockhead 1AD 10 months ago
Check Up: Rhythm (ASX:RHY) plans US expansion, the US$1.5b dog dermatitis market and data dumps drive stocks down

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

Stockhead 1AD 10 months ago
Closing Bell: More pain for investors as the ASX 200 falls for second consecutive day

The Aussie share market has fallen for two consecutive days, down by 0.46% today. Seven sectors were down, while four rose. Utilities and Mining were the worst peforming sectors, while Healtcare and IT were the best. In big cap news today,...

Stockhead 1AD 10 months ago
10 at 10: These ASX stocks are trading in the green amid a sea of red this morning

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Stockhead 1AD 10 months ago
Check up: A mixed bag for ASX health stocks as FDA decides fates at the flip of a coin

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Stockhead 1AD 10 months ago
Check Up: As Alzheimer’s grabs the spotlight, these ASX biotech stocks also impressed

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Stockhead 1AD 11 months ago
Hidden Gems Webinar Recap OEL, 1AD, HRZ & LRS

ShareCafeHidden Gems Webinar Recap OEL, 1AD, HRZ & LRS Catch up on the full webinar with presentations from Otto Energy (ASX:OEL), AdAlta Limited (ASX:1AD), Horizon Minerals Limited (ASX:HRZ) & Latin Resources Limited (ASX: LRS). H...

ShareCafe 1AD 11 months ago
A new approach to drug discovery

ShareCafeA new approach to drug discovery Presenter – Tim Oldham – CEO & Managing Director – Adalta Limited is a clinical-stage biotechnology company that uses its i-body platform to discover and develop next-generation protein therape...

ShareCafe 1AD 11 months ago
ASX in red: Will market snap a 3-session winning streak?

Summary The ASX 200 is trading lower by 8.60 points or 0.12% to 7,106.60 at the close, weighed down by energy and mining stocks. The healthcare sector was the worst performer, falling 0.87%, followed by energy, materials, and A-REIT....

Kalkine Media 1AD 1 year ago
AdAlta and GE Healthcare advance candidate to pre-clinical development

AdAlta (ASX:1AD) has announced that its commercial agreement with GE Healthcare is moving to the next phase following the successful identification of multiple i-bodies to be advanced into pre-clinical development for use as a poten...

BiotechDispatch 1AD 1 year ago
ASX Gains Amid Choppy Trade, Healthcare, Energy Stocks in High Spirits

Summary The ASX 200 trades higher by 15.20 points or 0.22% to 7045.50 at the close, led by gains in heavyweight healthcare and energy stocks. Retail player Kogan.Com and gold miner Silver Lake Resources are top performing stocks on the...

Kalkine Media 1AD 1 year ago
ASX set to close higher on tech rally, gets a boost from robust sales data

Summary The ASX 200 is set to close the week with narrow gains, led by a strong rally in healthcare and tech stocks. The top five gainers on the ASX are EML Payments, A2 Milk Company, Webjet, Nuix and Xero. Bitcoin staged a smart reco...

Kalkine Media 1AD 1 year ago